Filing Analysis
CytoSorbents Corporation held its 2026 Annual Meeting of Stockholders on August 13, 2026. Shareholders approved several key matters, most notably a proposal to amend the Certificate of Incorporation to authorize a reverse stock split with a ratio between 1-for-5 and 1-for-20.
🚩 Red Flags
- Approval of a reverse stock split (ratio up to 1-for-20) is often used to maintain Nasdaq listing compliance or boost share price due to low valuation.
- The necessity of such a split frequently indicates significant downward pressure on the stock price.
📋 Key Facts
- Annual Meeting held on August 13, 2026.
- Shareholders approved a reverse stock split ratio between 1-for-5 and 1-for-20; exact ratio to be determined by the Board within one year of the meeting.
- Five directors were elected: Dr. Phillip P. Chan, Michael Bator, Dr. Edward R. Jones, Alan D. Sobel, and Jiny Kim.
- WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for fiscal year 2026.
- Non-binding advisory vote on executive compensation was approved.
- Quorum was met with 42,487,327 shares represented out of 62,842,748 outstanding.
Cytosorbents Corporation filed an 8-K to furnish an investor presentation under Regulation FD. The filing does not contain material changes to operations, leadership, or financial structure.
📋 Key Facts
- Filed on August 7, 2026 (reporting date of August 6, 2026).
- The company furnished an investor presentation as Exhibit 99.1.
- Information is provided pursuant to Item 7.01 (Regulation FD Disclosure).
Cytosorbents Corporation filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a formal notice that a press release containing these results was issued on August 6, 2026.
📋 Key Facts
- The company announced financial results for the quarter ending June 30, 2026.
- The announcement was made via a press release dated August 6, 2026.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
CytoSorbents Corporation received a notice from Nasdaq stating it is non-compliant with the minimum Market Value of Listed Securities (MVLS) requirement. The company has been granted a 180-day grace period until December 28, 2026, to regain compliance.
🚩 Red Flags
- Failure to maintain minimum market value requirement ($35M) for Nasdaq Capital Market listing.
- Risk of delisting if compliance is not met by December 28, 2026.
- Potential need for dilutive equity raise to meet the $2.5 million stockholders' equity alternative.
📋 Key Facts
- Received notice from Nasdaq on June 29, 2026, regarding non-compliance with Nasdaq Listing Rule 5550(b)(2).
- The company's Market Value of Listed Securities (MVLS) has fallen below the required $35 million threshold.
- A 180-day compliance period has been granted, expiring on December 28, 2026.
- To regain compliance via MVLS, the market value must meet or exceed $35 million for at least 10 consecutive business days during the grace period.
- The company is also considering increasing stockholders' equity to at least $2.5 million as an alternative path to compliance.
CytoSorbents Corporation announced at the 2026 Life Sciences Forum that it has scheduled two pre-submission meetings with the FDA in August 2026. These meetings will focus on the company's ticagrelor and DOAC (Direct Oral Anticoagulant) programs.
📋 Key Facts
- Scheduled two pre-submission meetings with the FDA in August 2026.
- Meetings to discuss ticagrelor program.
- Meetings to discuss DOAC program.
- Presentation delivered at the 2026 Life Sciences Forum on June 24, 2026.
Cytosorbents Corporation announced its financial results for the first quarter ended March 31, 2026. The disclosure was made through a press release furnished as an exhibit to the filing.
📋 Key Facts
- The company reported financial results for the quarter ended March 31, 2026, on May 13, 2026.
- The results were disclosed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the performance was included as Exhibit 99.1.
Cytosorbents Corporation has been granted a 180-day extension by Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company now has until September 28, 2026, to meet the standard, failing which it may face delisting or be forced to implement a reverse stock split.
🚩 Red Flags
- Chronic non-compliance with Nasdaq listing rules (exceeding 180 days).
- Explicit mention of a potential reverse stock split, which often precedes further share price volatility.
- Risk of delisting if the stock price does not recover organically or through corporate action by September 2026.
📋 Key Facts
- Extension notice received from Nasdaq on April 1, 2026.
- New compliance deadline set for September 28, 2026.
- Original deficiency notice was issued on October 2, 2025, after 30 consecutive business days below $1.00.
- Compliance requires a closing bid price of at least $1.00 for 10 consecutive trading days.
- The company explicitly identified a reverse stock split as a potential option to regain compliance.
Cytosorbents Corporation announced its financial results for the fourth quarter and full year ended December 31, 2025. The announcement was made via a press release on March 25, 2026, and furnished under Items 2.02 and 7.01.
📋 Key Facts
- Reporting period: Quarter and fiscal year ended December 31, 2025.
- Filing date: March 25, 2026.
- The company furnished a press release as Exhibit 99.1.
- The filing was signed by CEO Dr. Phillip P. Chan.
Cytosorbents Corp filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal mechanism to furnish quarterly earnings press releases.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- The company issued a press release (Exhibit 99.1) containing financial results.
- CEO Dr. Phillip P. Chan signed the filing.
CytoSorbents Corporation received a notice from Nasdaq stating it is non-compliant with the Minimum Bid Price Requirement after its stock fell below $1.00 for 30 consecutive business days. The company has until March 31, 2026, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price has been below $1.00 for 30 consecutive business days
- Risk of being delisted if compliance is not met by March 2026
📋 Key Facts
- Received written notice from Nasdaq on October 2, 2025.
- Non-compliance is due to violation of Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement).
- The company has a compliance deadline of March 31, 2026.
- To regain compliance, the stock must close at or above $1.00 for at least 10 consecutive business days before the deadline.
CytoSorbents Corp issued an 8-K to furnish a press release regarding a regulatory update for its DrugSorb™-ATR product. The filing serves as a Regulation FD disclosure mechanism.
📋 Key Facts
- Date of report: September 16, 2025
- Subject matter: Regulatory update on DrugSorb™-ATR
- The information is furnished under Item 7.01 (Regulation FD Disclosure) and incorporated by reference into Item 8.01.
CytoSorbents Corporation announced the outcome of its appeal to the FDA regarding a previous denial of De Novo Market Authorization for DrugSorb™-ATR. The filing serves as a formal notification that the company has received a decision on this critical regulatory milestone.
🚩 Red Flags
- Regulatory setback: The context involves a prior FDA denial for a key product (DrugSorb™-ATR), which represents significant clinical/commercial risk.
📋 Key Facts
- The announcement concerns an appeal to the U.S. FDA regarding a prior denial of De Novo Market Authorization for DrugSorb™-ATR.
- The outcome was announced via press release on August 20, 2025.
- The filing is categorized under Item 8.01 (Results of Operation and Financial Condition).
Cytosorbents Corp filed an 8-K to announce its quarterly financial results for the period ending June 30, 2025. The filing serves as a formal notice that earnings data has been released via press release.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Quarter ended June 30, 2025
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Filed under Item 2.02 (Results of Operation and Financial Condition).
CytoSorbents Corporation issued a press release regarding new clinical study results demonstrating the efficacy of CytoSorb® therapy in treating sepsis and septic shock. The company also announced an upcoming webinar scheduled for September 10, 2025.
📋 Key Facts
- Issued press release on July 31, 2025, regarding clinical study results for CytoSorb® therapy.
- The studies focus on the mechanism of action and efficacy in treating sepsis and septic shock.
- Scheduled a World Sepsis Day Global Webinar for September 10, 2025.
CytoSorbents Corporation reported significant regulatory setbacks involving both the US FDA and Health Canada. The company is facing an FDA appeal hearing for a supervisory review and has received a Notice of Refusal from Health Canada regarding its Medical Device License application.
🚩 Red Flags
- Regulatory rejection from Health Canada (Notice of Refusal) creates uncertainty regarding international market expansion.
- FDA supervisory review appeal indicates ongoing friction or disagreement with regulatory authorities regarding product safety/efficacy data.
- Potential delay in revenue generation due to pending medical device licenses.
📋 Key Facts
- The U.S. FDA has scheduled an appeal hearing date for the Company’s supervisory review under 21 CFR 10.75.
- Health Canada issued a Notice of Refusal of the Company’s Medical Device License application due to non-compliance with certain Medical Devices Regulations.
- The Company plans to file a Level 1 'Request for Reconsideration' with Health Canada by July 25, 2025.
CytoSorbents Corporation has announced its intention to appeal a U.S. FDA denial letter regarding its De Novo Request for DrugSorb-ATR. This represents a significant regulatory setback for the company's product pipeline.
🚩 Red Flags
- Regulatory setback: The denial of a De Novo request is a significant hurdle for product commercialization and revenue growth.
- Uncertainty regarding timeline and outcome of the appeal process.
📋 Key Facts
- The filing is dated June 24, 2025.
- The company received a denial letter from the FDA regarding its De Novo Request for DrugSorb-ATR.
- Management has officially decided to appeal the FDA's decision.
- The announcement was made via press release (Exhibit 99.1).
CytoSorbents Corporation held its 2025 Annual Meeting of Stockholders on June 12, 2025. The meeting resulted in the election of five directors, advisory approval of executive compensation, and ratification of WithumSmith+Brown, PC as the independent auditor.
🚩 Red Flags
- High number of 'Broker Non-Votes' (17,419,927 shares) across all proposals suggests a significant portion of the voting power was not exercised on these specific items.
📋 Key Facts
- Annual Meeting held on June 12, 2025.
- Five directors were elected to serve until the 2026 Annual Meeting: Dr. Phillip P. Chan, Dr. Edward R. Jones, Michael Bator, Alan D. Sobel, and Jiny Kim.
- Non-binding advisory approval of named executive officer compensation was obtained.
- Ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Quorum was established by 40,071,481 shares (out of 62,610,376 outstanding) being represented in person or by proxy.
CytoSorbents Corporation announced that its Series B Right Warrants expired worthless because the company's 5-day volume weighted average price fell below the $2.00 minimum requirement set in the Prospectus.
🚩 Red Flags
- Failure to maintain a minimum stock price of $2.00, which triggered the expiration of warrants.
- Potential liquidity/capital raising failure: The expiration of these warrants suggests the company failed to meet the conditions necessary to secure capital through this specific rights offering mechanism.
- Stock price weakness: The VWAP being below $2.00 indicates significant downward pressure on the share price.
📋 Key Facts
- The 5-day VWAP prior to June 10, 2025, was lower than the required $2.00 threshold.
- Series B Right Warrants issued via a previous Rights Offering have expired worthless.
- Any payments received for warrant exercises that were not applied will be refunded without interest or penalty.
- The event is reported under Item 7.01 (Regulation FD Disclosure).
CytoSorbents Corporation filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025. The filing serves as a formal announcement of the company's recent operational and financial performance.
📋 Key Facts
- Report date: May 14, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Company is listed on the Nasdaq Capital Market under ticker CTSO.
CytoSorbents Corporation announced that the FDA has issued a denial letter regarding its De Novo Request for DrugSorb-ATR, citing remaining deficiencies. The company is attempting to resolve these issues through interactive conversations with the FDA or via a formal appeal.
🚩 Red Flags
- Regulatory setback for a key product (DrugSorb-ATR) impacting potential U.S. commercialization.
- Uncertainty regarding the timeline and outcome of FDA resolution or formal appeal process.
📋 Key Facts
- FDA issued a denial letter for the De Novo Request for DrugSorb-ATR.
- The denial identified 'remaining deficiencies' that must be addressed before commercialization in the U.S. is authorized.
- The company plans to engage in interactive conversations with the FDA to resolve issues.
- If discussions fail, a formal appeal will be filed within 60 days of receipt of the denial letter.
CytoSorbents Corporation announced the appointment of Melanie Grossman as Vice President and Corporate Controller on April 17, 2025. The appointment includes an inducement grant of stock options and restricted stock units to align her interests with shareholders.
🚩 Red Flags
- Significant portion of equity compensation (70,000 total units) is tied specifically to 'Change-of-Control' events, which can sometimes incentivize management to seek a sale rather than long-term organic growth.
📋 Key Facts
- Melanie Grossman appointed as VP and Corporate Controller; anticipated start date was April 14, 2025.
- Inducement grant includes 25,000 Non-Qualified Stock Options with an exercise price of $0.99 (FMV as of April 14, 2025) and a 10-year term.
- Stock options vest over three years: 50% at year one, 25% at year two, and 25% at year three.
- Grant includes 35,000 Restricted Stock Units (RSUs) vesting upon change-in-control or a 4-year cliff.
- Grant includes 35,000 Change-of-Control RSUs that vest only in the event of a change-in-control.
CytoSorbents Corporation announced the appointment of Thomas Shannon as the new Vice President of Marketing for North America on April 14, 2025.
📋 Key Facts
- Appointment of Thomas Shannon as Vice President of Marketing for North America.
- Announcement date: April 14, 2025.
- The filing is a Regulation FD disclosure regarding a press release.
CytoSorbents Corporation has announced an extension for the expiration of its Series B Right Warrants. The deadline to exercise these warrants has been moved from April 10, 2025, to June 10, 2025.
🚩 Red Flags
- Extension of warrant expiration dates can sometimes indicate difficulty in having holders exercise their rights, potentially due to the current stock price being below the exercise price (out-of-the-money).
📋 Key Facts
- The company issued a press release on April 4, 2025, regarding the extension of Series B Right Warrants.
- The original expiration date for the warrants was April 10, 2025.
- The new expiration date is June 10, 2025.
- The warrants were issued in connection with a previously announced rights offering.
CytoSorbents Corporation filed an 8-K to furnish its financial results for the quarter and fiscal year ended December 31, 2024. The filing serves as a formal announcement of the company's quarterly earnings release.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- The filing includes Exhibit 99.1 containing the press release of financial results.
CytoSorbents Corporation has determined that its previously issued financial statements for the fiscal year ended December 31, 2023, and various quarterly reports in 2023 and 2024 can no longer be relied upon. The restatement is due to clerical errors in inventory valuation and incorrect application of accounting policies regarding restricted stock unit (RSU) compensation.
🚩 Red Flags
- Non-reliance on previously issued financial statements (Item 4.02) is a significant indicator of internal control weaknesses.
- Errors span multiple reporting periods (FY2023 and portions of FY2024), suggesting systemic issues in the accounting close process.
- The restatement involves both inventory (asset valuation) and stock-based compensation (equity/expense timing), which impacts both the balance sheet and income statement.
📋 Key Facts
- The company determined that consolidated financial statements for the year ended December 31, 2023, are unreliable.
- Interim unaudited condensed consolidated financial statements for the first three quarters of FY2023 and FY2024 are also affected.
- Errors identified include an overstatement of inventory due to a clerical error.
- Errors identified include an understatement of non-cash restricted stock expense related to RSU accounting policy errors (incorrectly using vesting date fair value instead of grant date).
- The company plans to restate these figures in its upcoming 2024 Annual Report.
CytoSorbents Corporation has issued a press release reaffirming its preliminary financial expectations for the fiscal year and quarter ended December 31, 2024. The company also announced that its earnings call for this period has been rescheduled to March 31, 2025.
🚩 Red Flags
- Delay in reporting actual financial results (earnings call rescheduled).
📋 Key Facts
- Reaffirmed previously disclosed preliminary financial expectations for Q4 and FY 2024.
- Rescheduled the earnings call for the quarter and year ended December 31, 2024.
- The rescheduled earnings call is now expected to occur on March 31, 2025.
CytoSorbents Corporation has announced a delay of its earnings call, originally scheduled for an earlier date, now expected on March 25, 2025. The delay is attributed to the sudden passing of the Company’s Vice President and Corporate Controller.
🚩 Red Flags
- Sudden loss of key executive (VP and Corporate Controller) during earnings season.
- Delay in reporting financial results can sometimes signal internal control issues or audit delays, though here it is explicitly attributed to personnel loss.
📋 Key Facts
- Earnings call for the quarter/year ended December 31, 2024, rescheduled to March 25, 2025.
- The delay is due to the death of the VP and Corporate Controller.
- Company reaffirmed previously disclosed preliminary financial expectations for Q4 and FY2024.
CytoSorbents Corporation announced the expiration of its Series A Right Warrants and the subsequent exercise of 1,417,208 warrants. The company received $1.6 million in aggregate gross proceeds from this exercise.
🚩 Red Flags
- Dilution risk for existing shareholders due to the issuance of new shares upon warrant exercise.
📋 Key Facts
- Expiration of Series A Right Warrants occurred on February 25, 2025.
- Total aggregate gross proceeds: $1.6 million.
- Number of warrants exercised: 1,417,208 units.
- Exercise price per warrant: $1.13.
CytoSorbents Corporation announced the conclusion of its Rights Offering subscription period and provided preliminary financial results for the quarter and year ended December 31, 2024.
🚩 Red Flags
- Reliance on a Rights Offering suggests a need for immediate capital infusion to support operations or liquidity.
📋 Key Facts
- Rights Offering commenced on December 9, 2024.
- Subscription period has concluded as of January 13, 2025.
- Company released preliminary and unaudited financial results for the quarter and year ended December 31, 2024.
- The filing includes business updates alongside the financial results.
CytoSorbents Corporation announced the opening of a new regional sales subsidiary located in Dubai, United Arab Emirates. This move is intended to expand the company's commercial presence and sales capabilities within the Middle East region.
📋 Key Facts
- Company opened a new regional sales subsidiary in Dubai, UAE.
- Announcement date: January 6, 2025.
- The filing was submitted via Item 8.01 (Other Events).
CytoSorbents Corporation issued an 8-K to announce preliminary and unaudited financial results and business updates for the fiscal year and quarter ended December 31, 2024.
📋 Key Facts
- Report date: January 3, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- The filing contains preliminary and unaudited financial results via Exhibit 99.1.
CytoSorbents Corporation announced the commencement of its previously planned rights offering on December 23, 2024. This filing serves as a formal notice to shareholders regarding the execution of this equity financing.
🚩 Red Flags
- Rights offerings are often used by micro-cap companies to raise capital when traditional debt or equity financing is unavailable, potentially signaling liquidity constraints.
📋 Key Facts
- Company commenced its previously announced rights offering on December 23, 2024.
- The announcement was made via press release (Exhibit 99.1).
- The filing is categorized under Item 7.01 (Regulation FD Disclosure).
CytoSorbents Corporation announced the commencement of a shareholder rights offering on December 9, 2024. The company has entered into a Dealer-Manager Agreement with Moody Capital Solutions, Inc. to facilitate the offering.
🚩 Red Flags
- Rights offerings in micro-cap companies are often used to raise urgent capital to address liquidity constraints or working capital needs.
- Potential for significant dilution of existing shareholders through the issuance of new shares and warrants.
📋 Key Facts
- Rights Offering commenced on December 9, 2024.
- The offering is being conducted via an S-3 Registration Statement (File No. 333-281062).
- Record date for eligible stockholders and warrantholders is set for approximately December 16, 2024.
- Moody Capital Solutions, Inc. has been appointed as the Dealer-Manager.
- The offering includes various warrant certificates (Series A and Series B) as part of the structure.
CytoSorbents Corporation filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal mechanism to furnish the earnings press release to the SEC.
📋 Key Facts
- The company announced financial results for the fiscal quarter ending September 30, 2024.
- The announcement was made via press release on November 7, 2024.
- The filing is pursuant to Item 2.02 (Results of Operation and Financial Condition).
CytoSorbents Corporation has authorized an 'at the market' (ATM) equity offering of common stock up to a maximum aggregate amount of $20,000,000. The offering is conducted under an existing S-3 registration statement and an Open Market Sale Agreement with Jefferies LLC.
🚩 Red Flags
- Potential for immediate share dilution to existing shareholders via the ATM offering.
- ATM offerings are often used by micro-cap companies to raise working capital, which can signal a need for liquidity.
📋 Key Facts
- Maximum aggregate offering amount: $20,000,000 in Common Stock.
- Offering type: 'At the market' (ATM) equity offering under a Form S-3 registration statement.
- The S-3 was declared effective by the SEC on September 30, 2024.
- The sale is governed by an Open Market Sale Agreement dated December 30, 2021, with Jefferies LLC.
- Legal opinion regarding the legality of the issuance was provided by Morgan, Lewis & Bockius LLP.
CytoSorbents Corporation announced preliminary financial results for the quarter ended September 30, 2024, and provided updates on regulatory milestones for its DrugSorb™-ATR medical device. The company has submitted a De Novo marketing application to the FDA and completed a Health Canada license application.
📋 Key Facts
- Announced preliminary financial results for Q3 2024 (ended Sept 30, 2024) via press release.
- Submitted DrugSorb™-ATR De Novo marketing application to the FDA for reducing perioperative bleeding in patients on ticagrelor.
- DrugSorb-ATR holds FDA Breakthrough Device Designation, making it eligible for priority review.
- Completed Health Canada Medical Device License application; submission pending MDSAP certification.
CytoSorbents Corporation entered into an Amended and Restated Letter Agreement with ROKK, LLC to redefine the scope of 'gross revenue' for a perpetual 3% royalty on CytoSorb device sales. The amendment clarifies how revenues from licensing, sub-licensing, and IP dispositions are calculated within specific medical fields.
🚩 Red Flags
- Perpetual royalty obligation on flagship product revenue can impact long-term margins.
- The amendment includes 'net amount of any proceeds from the disposition of the Company’s intellectual property,' meaning a sale of IP would trigger an immediate royalty payment.
📋 Key Facts
- Amended and Restated Agreement entered into with ROKK, LLC on August 16, 2024.
- Perpetual royalty rate remains unchanged at three percent (3%) of gross revenues.
- Redefines 'gross revenue' to include: (i) GAAP recognized revenue in sepsis, cardio-pulmonary bypass, organ donation, chemotherapy, and inflammation control; (ii) payments from third-party licensees/sub-licensees; and (iii) net proceeds from IP dispositions related to the Covered Product.
- Covered Products include CytoSorb, VetResQ, ECOS-300CY, DrugSorb, and DrugSorb-ATR.
CytoSorbents Corporation announced the appointment of Peter J. Mariani as Chief Financial Officer, effective August 14, 2024. This follows the retirement of the previous CFO, Kathleen P. Bloch, who will transition into a consulting role to assist with the leadership handover.
🚩 Red Flags
- Transition period involves a high-cost consulting arrangement ($335/hr) for the outgoing CFO through end of 2025.
- Significant equity inducement awards granted to new CFO may lead to future dilution.
📋 Key Facts
- Peter J. Mariani appointed CFO effective August 14, 2024; term ends December 31, 2025 (with automatic one-year renewals).
- Mariani's compensation includes a $425,000 annual base salary and an annual cash bonus of up to 45% of base salary.
- Significant inducement awards granted to Mariani: 80,000 time-based RSUs, 215,000 performance-based stock options, 65,000 RSUs (vesting in two installments), 175,000 Change in Control RSUs, and 110,000 signing RSUs.
- Kathleen P. Bloch retired as CFO and entered a consulting agreement through December 31, 2025, at an hourly rate of $335/hour.
- Mariani brings extensive medical technology leadership experience, previously serving as EVP & CFO of Axogen, Inc.
CytoSorbents Corporation filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal notice that a press release containing these results was issued on August 13, 2024.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing is a standard announcement of quarterly financial results via press release (Exhibit 99.1).
CytoSorbents Corporation has regained compliance with Nasdaq's minimum bid price requirement after its stock closed at or above $1.00 for 10 consecutive business days. This resolves the deficiency notice previously issued in May 2024.
🚩 Red Flags
- History of delisting risk due to sub-$1.00 share price (previously reported in May 2024).
📋 Key Facts
- The company achieved a minimum closing price of at least $1.00 per share for 10 consecutive business days between July 12 and July 25, 2024.
- Nasdaq has officially considered the compliance matter regarding Rule 5550(a)(2) closed.
- The deficiency was originally triggered by the stock closing below $1.00 for 30 consecutive business days prior to May 22, 2024.
CytoSorbents Corporation entered into a $20 million Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P. to fund working capital and general business requirements. The financing includes high-interest variable rates and significant equity warrants/conversion options.
🚩 Red Flags
- High cost of capital: Interest rate floor of 13.50% is significantly above standard market rates for non-distressed debt.
- Equity Dilution: Issuance of warrants for over 1.6 million shares and conversion options poses significant dilution risk to existing shareholders.
- Collateralization: The company has pledged its intellectual property as collateral, which is a critical asset for a biotech/medical device firm.
- Restrictive Covenants: Includes customary but strict negative covenants and events of default related to insolvency or material adverse effects.
📋 Key Facts
- Total commitment of up to $20 million via two tranches: $15M (Tranche 1) and $5M (Tranche 2).
- Interest rate is the greater of Prime + 5.00% or a floor of 13.50% per annum.
- The loan is secured by a first priority security interest in Company shares and collateral, including intellectual property.
- Lenders received warrants to purchase 1,645,569 shares of common stock.
- Lenders have a conversion option to convert up to $2 million of principal into common stock at 120% of the Closing Price.
- Repayment maturity is set for July 1, 2027 (or January 1, 2028, if Tranche 2 is fully drawn).
CytoSorbents Corporation held its 2024 Annual Meeting of Stockholders on June 6, 2024. The meeting resulted in the successful election of five directors and the approval of several key shareholder proposals, including executive compensation and auditor ratification.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 6, 2024.
- Five directors were elected: Dr. Phillip P. Chan, Michael Bator, Dr. Edward R. Jones, Alan D. Sobel, and Jiny Kim.
- Shareholders approved the compensation of named executive officers on an advisory basis (Say-on-Pay).
- Shareholders approved an amendment to the 2014 Long-term Incentive Plan.
- WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Quorum was met with 40,028,453 shares represented out of 54,306,415 outstanding shares.
CytoSorbents Corporation received a notice from Nasdaq stating it is non-compliant with the Minimum Bid Price Requirement after its stock fell below $1.00 for 30 consecutive business days. The company has until November 16, 2024, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock trading below the $1.00 minimum threshold (penny stock territory)
- Risk of delisting if compliance is not met by November 2024
📋 Key Facts
- Received written notice from Nasdaq on May 20, 2024.
- Non-compliance is due to violation of Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement).
- The stock price fell below $1.00 per share for 30 consecutive business days.
- Compliance deadline: November 16, 2024.
- Requirement to regain compliance: Closing bid price must be $\ge$ $1.00 for at least 10 consecutive business days before the Compliance Date.
CytoSorbents Corporation filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024. The filing serves as a formal notice that earnings data has been released via press release.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: Quarter ended March 31, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
CytoSorbents Corporation announced the adoption of its Second Amended and Restated Bylaws on May 2, 2024. The amendments primarily focus on aligning company bylaws with recent changes to Delaware General Corporation Law (DGCL).
📋 Key Facts
- Board approved Second Amended and Restated Bylaws effective May 2, 2024.
- Removed requirement to make stockholder lists available for examination at meetings, per DGCL updates.
- Updated advance notice requirements for stockholder proposals and director nominations.
- Deleted the requirement that stockholder action must be effected only at a duly called meeting (allowing for more flexible shareholder actions).
- Added a forum selection clause requiring internal affairs litigation in Delaware state court and securities-related litigation in federal court.
CytoSorbents Corporation has implemented a voluntary salary reduction program for its named executive officers as part of broader cost-cutting measures. In exchange for reducing base salaries through December 31, 2024, executives will receive nonqualified stock options equal to the value of their lost wages.
🚩 Red Flags
- Cost-cutting measures involving executive pay often signal liquidity constraints or a need to preserve cash runway.
- The use of stock options as compensation for salary reductions can lead to future dilution.
📋 Key Facts
- Effective date of salary reductions: April 1, 2024, through December 31, 2024.
- CEO Phillip P. Chan agreed to a 35% base salary reduction ($123,498.43).
- Other named executives (CFO, COO, CMO) agreed to a 15% base salary reduction.
- Salaries are scheduled to automatically restore to original levels on January 1, 2025.
- Compensation for the reduction is via nonqualified stock options under the 2014 Long-Term Incentive Plan.
- The option value was calculated using the March 28, 2024, closing price of $0.95 per share.
CytoSorbents Corporation filed an 8-K to furnish its quarterly and annual financial results for the period ended December 31, 2023. The filing serves as a formal announcement of the company's earnings release.
📋 Key Facts
- Report date: March 14, 2024
- Reporting period: Quarter and twelve-months ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 regarding financial results.
CytoSorbents Corporation issued a press release regarding positive results from a randomized controlled trial (RCT) involving CytoSorb® blood purification during heart transplants. The study findings were published in the ESC Heart Failure journal.
📋 Key Facts
- Published clinical data in the European Society of Cardiology journal, 'ESC Heart Failure'.
- The study was a randomized controlled trial (RCT) evaluating CytoSorb® blood purification during heart transplant procedures.
- Company reports 'excellent outcomes' from the trial.